Safety Profile Comparison (2026 Data) Risk Factor Semaglutide (GLP-1) Bariatric Surgery Invasiveness Non-invasive (Injection) Invasive (Surgery) Common Risks Nausea, Vomiting, Constipation Infection, Bleeding, Blood Clots Serious Risks Pancreatitis, Gastroparesis Dumping Syndrome, Malnutrition Anesthesia Risk None Standard Surgical Risk Reversibility Fully Reversible Generally Permanent 2
Isoprenoid derivatives of lysophosphatidylcholines (LPCs), such as cytronellic acid- lysophosphatidylcholine (1-CA-LPC) stimulated GLP-1 secretion from GLUTag cells through GPR55, GPR119, and GPR120 [149] (Fig
These medications not only improve glycaemic control but also reduce hepatic steatosis, liver enzyme levels, and inflammation, with some potential to address fibrosis
This can affect the digestion and absorption of dietary fats and fat-soluble vitamins (A, D, E, K), but does not impact the injectable medication itself
The drug works the same way regardless of these factors